Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses: 2024-2025

  • Zhengye Biotechnology Holding's Accumulated Expenses was N/A to $523,978 in Q2 2025 from the same period last year, while for Jun 2025 it was $523,978, marking a year-over-year change of. This contributed to the annual value of $352,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Accumulated Expenses of $523,978 as of Q2 2025, which was up 46.39% from $357,924 recorded in Q4 2024.
  • Zhengye Biotechnology Holding's Accumulated Expenses' 5-year high stood at $523,978 during Q2 2025, with a 5-year trough of $357,924 in Q4 2024.
  • Its 2-year average for Accumulated Expenses is $440,951, with a median of $440,951 in 2024.